The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP ‐1/ GIP receptor agonist ( BGM0504 ) in healthy volunteers: A dose‐escalation Phase I study

Documenti analoghi

• Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers
  di: Irina Baltcheva, et al.
  Pubblicazione: (2026)
• Pharmacokinetics, pharmacodynamics, and safety of frunexian in healthy Chinese volunteer adults: A randomized dose‐escalation phase I study
  di: Jia‐yu Zhang, et al.
  Pubblicazione: (2024)
• Evaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double‐Blind Phase II Trial
  di: Ping Jin, et al.
  Pubblicazione: (2026)
• Phase I clinical trial evaluating the safety, tolerance, pharmacokinetics and pharmacodynamics of HSK21542 injection in healthy volunteers
  di: Rong Shao, et al.
  Pubblicazione: (2024)
• Phase I study of the oral GLP ‐1 receptor agonist DA ‐ 302168S : Safety, pharmacokinetics, and pharmacodynamics in healthy and overweight/obese adults
  di: Liang Zheng, et al.
  Pubblicazione: (2025)